Medicus Pharma Submits Optimized Phase 2 Study Design for Teverelix

Why It Matters

A faster, smaller Phase 2 trial could quickly validate Teverelix’s efficacy in an unmet AUR market, accelerating regulatory approval and revenue potential.

Key Takeaways

• Phase 2 design targets 12‑week prostate volume reduction.
• Sample size cut from 390 to 126 patients.
• Interim analysis after enrolling half participants of the planned cohort.
• Evaluates intramuscular vs subcutaneous dosing routes for optimal drug delivery.
• FDA feedback expected within 30 days for decision.

Summary

Medicus Pharma announced that it has submitted an optimized Phase 2 trial design to the FDA for Teverelix, its novel GnRH antagonist aimed at preventing relapse of acute urinary retention (AUR) in men with enlarged prostates. The new protocol pivots from a traditional large‑scale study to a streamlined, mechanistic approach that focuses on a clear pharmacodynamic endpoint—reduction in prostate volume measured at 12 weeks.

The redesign slashes the planned enrollment from roughly 390 participants to about 126, with an interim analysis after half the cohort is enrolled. It also compares intramuscular and subcutaneous administration routes to identify the optimal dosing strategy. By targeting an early, objective readout, the trial promises faster, data‑driven go‑/no‑go decisions and lower development costs.

Dr. Faisal Mehmud, Chief Medical Officer, emphasized that the company “moved to a much more mechanistic driven design,” building on prior Phase 2 data that showed over a 10% prostate volume reduction within four weeks and corresponding improvements in urinary flow. He noted the absence of approved pharmacologic options for AUR, underscoring the potential therapeutic gap Teverelix could fill.

If the FDA provides feedback within the anticipated 30‑day window, Medicus could accelerate subsequent development stages, positioning Teverelix as a first‑in‑class oral therapy for AUR. The streamlined trial design reduces risk, shortens timelines, and could attract partnership or licensing interest, enhancing the company’s valuation and market prospects.

Original Description

Medicus Pharma Chief Medical Officer Dr Faisal Mehmud joined Steve Darling from Proactive to announce that the company has submitted an optimized Phase 2 clinical study design to the U.S. Food and Drug Administration for Teverelix. The therapy is being developed to help prevent recurrent acute urinary retention (AUR) in men with benign prostatic hyperplasia (BPH) under the company’s existing open Investigational New Drug application.

Mehmud explained that the updated study design has been refined under the leadership of Steven A. Kaplan, MD, FACS, a globally recognized expert in urology and men’s health, who will serve as Principal Investigator.

He noted that there are currently no approved pharmacological therapies specifically indicated to prevent the recurrence of AUR, which is most caused by an enlarged prostate. Medicus Pharma’s proof-of-concept approach for Teverelix aims to address this unmet need, targeting a market estimated at approximately $2 billion.

The revised Phase 2 study design, known as ANT-2111-02, includes a targeted sample size of approximately 126 patients across sites in the United States and Europe. The study is designed to detect a clear pharmacodynamic signal, specifically total prostate volume reduction, within an expected timeframe of about 12 weeks.

The optimized design reflects a data-driven approach, reducing the study size by roughly threefold compared to the original plan. This adjustment is expected to significantly lower development costs while improving efficiency and execution speed. The streamlined approach also positions the company for earlier strategic engagement and potential partnering discussions.

#proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #ClinicalTrials #Phase2 #Teverelix #Biotech #DrugDevelopment #FDA #Urology #BPH #AUR #MensHealth #PharmaInnovation #Healthcare #MedicalResearch #Biopharma